Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-na⟨ve advanced non-small-cell lung cancer in the era of third-generation agents

被引:7
|
作者
Jiang, Jingwei [1 ,2 ]
Liang, Xiaohua [1 ,2 ]
Zhou, Xinli [1 ,2 ]
Huang, Ruofan [1 ,2 ]
Chu, Zhaohui [1 ,2 ]
Zhan, Qiong [1 ,2 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Oncol, Shanghai 200040, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200040, Peoples R China
基金
中国国家自然科学基金;
关键词
Carcinoma; Non-small-cell lung; Chemotherapy; Platinum; Third-generation agents; Meta-analysis; RANDOMIZED PHASE-II; PACLITAXEL PLUS CARBOPLATIN; GEMCITABINE-DOCETAXEL; 1ST-LINE TREATMENT; VINORELBINE; CHEMOTHERAPY; CISPLATIN; TRIAL; COMBINATION; METAANALYSIS;
D O I
10.1007/s00432-012-1294-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim was to compare the efficacy between doublets of third-generation agents (non-platinum) and doublets of platinum plus a third-generation agent (platinum-based) for chemotherapy-na < ve advanced non-small-cell lung cancer (NSCLC). We conducted a literature-based meta-analysis to compare the efficacy between doublets of third-generation agents and doublets of platinum plus a third-generation agent for chemotherapy-na < ve advanced NSCLC. The primary end point was overall survival, and the secondary end points were progression-free survival (PFS) and response rate. Subgroup analyses were also conducted by different non-platinum doublet regimens or different platinum-based doublets. A descriptive review for toxicity was performed. Sixteen randomized controlled trials were identified ultimately. Results demonstrated that the efficacy of non-platinum doublets was comparable with platinum-based doublets according to the overall survival (HR = 1.03, 95 % CI = 0.98-1.08, p = 0.29). Subgroup analyses by different non-platinum doublets also showed the efficacy of all the third-generation doublets, such as vinorelbine plus gemcitabine, vinorelbine plus paclitaxel, gemcitabine plus paclitaxel, and gemcitabine plus docetaxel, was comparable with platinum-based doublets (HR = 1.00, 95 % CI = 0.78-1.27, p = 0.98; HR = 0.97, 95 % CI = 0.80-1.18, p = 0.79; HR = 1.05, 95 % CI = 0.99-1.12, p = 0.11; HR = 1.01, 95 % CI = 0.92-1.10, p = 0.87; respectively). Subgroup analyses by different platinum-based doublets indicated that the efficacy of the third-generation doublets were equal to both cisplatin-based doublets and carboplatin-based doublets (HR = 1.08, 95 % CI = 1.00-1.17, p = 0.05; HR = 1.00, 95 % CI = 0.94-1.05, p = 0.94; respectively). The secondary end points indicated that platinum-based doublets might have an advantage in PFS but not in response rate (HR = 1.06, 95 % CI = 1.01-1.12, p = 0.03; RR = 0.99, 95 % CI = 0.90-1.08, p = 0.81; respectively). Non-platinum doublets were as effective as platinum-based doublets with different toxicity profile for chemotherapy-na < ve advanced NSCLC in the era of third-generation agents.
引用
收藏
页码:25 / 38
页数:14
相关论文
共 50 条
  • [31] Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Rizvi, Naiyer A.
    Hellmann, Matthew D.
    Brahmer, Julie R.
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Gettinger, Scott
    Chow, Laura Q.
    Gerber, David E.
    Laurie, Scott A.
    Goldman, Jonathan W.
    Shepherd, Frances A.
    Chen, Allen C.
    Shen, Yun
    Nathan, Faith E.
    Harbison, Christopher T.
    Antonia, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2969 - +
  • [32] Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation
    Tanaka, Ichidai
    Morise, Masahiro
    Miyazawa, Ayako
    Kodama, Yuta
    Tamiya, Yutaro
    Gen, Soei
    Matsui, Akira
    Hase, Tetsunari
    Hashimoto, Naozumi
    Sato, Mitsuo
    Hasegawa, Yoshinori
    CLINICAL LUNG CANCER, 2020, 21 (03) : 273 - +
  • [33] Incidence of chemotherapy discontinuation and characteristics of elderly patients with non-small cell lung cancer treated with platinum- based doublets
    Alexa, Teodora
    Lavinia, Anti
    Luca, Andrei
    Miron, Lucian
    Alexa, Ioana Dana
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2014, 18 (05): : 340 - 343
  • [34] Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents
    Kogo, Mari
    Sunaga, Tomiko
    Nakamura, Shoko
    Akita, Takahiro
    Kurihara, Tatsuya
    Shikama, Yusuke
    Nakajima, Hiroaki
    Tobe, Takashi
    Yoneyama, Keiichiro
    Kiuchi, Yuji
    CHEMOTHERAPY, 2017, 62 (04) : 239 - 245
  • [35] Non-platinum-based paclitaxel combinations in advanced non-small-cell lung cancer
    Le Chevalier, T
    ONCOLOGY-NEW YORK, 1999, 13 (09): : 48 - 50
  • [37] RICTOR polymorphisms affect efficiency of platinum-based chemotherapy in Chinese non-small-cell lung cancer patients
    Wang, Shiming
    Song, Xiao
    Li, Xiaoying
    Zhao, Xueying
    Chen, Hongyan
    Wang, Jiucun
    Wu, Junjie
    Gao, Zhiqiang
    Qian, Ji
    Han, Baohui
    Bai, Chunxue
    Li, Qiang
    Lu, Daru
    PHARMACOGENOMICS, 2016, 17 (15) : 1637 - 1647
  • [38] miRNAs as biomarkers of adverse drug reactions to platinum-based agents in patients with non-small-cell lung cancer
    Vasconcelos, Pedro E. N. S.
    Visacri, Marilia B.
    Pincinato, Eder de C.
    Torso, Nadine de G.
    Seguin, Cecilia S.
    Zambon, Lair
    Barbeiro, Aristoteles de S.
    Mauricio, W. P. Junior
    Moriel, Patricia
    BIOMARKERS IN MEDICINE, 2021, 15 (13) : 1067 - 1070
  • [39] Patients Treated With Platinum-Doublet Chemotherapy for Advanced Non-Small-Cell Lung Cancer Have Inferior Outcomes If Previously Treated With Platinum-based Chemoradiation
    Paramanathan, Ashvin
    Solomon, Benjamin
    Collins, Marnie
    Franco, Michael
    Kofoed, Sarah
    Francis, Heather
    Ball, David
    Mileshkin, Linda
    CLINICAL LUNG CANCER, 2013, 14 (05) : 508 - 512
  • [40] A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer
    Ballas, MS
    Dennis, PA
    CANCER BIOLOGY & THERAPY, 2005, 4 (12) : 1316 - 1317